Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.

A later paper about NCT02065791. The trial’s primary report, PMID 30990260, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 4,401 people · 2021

Range includes no effect

Doesn’t vote: a later paper about the trial

−23%−45% to +8%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.77, 95% CI 0.55–1.08

the abstract, start to end

… with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]).

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.770.55–1.08

SGLT2 inhibitorsCardiovascular events

1 / 3

2021

2022

2023

2024

2025

2026

this paperpooled itcites it